Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Ruxolitinib versus Dexamethasone in Hospitalized Adults with Covid-19: multicenter matched-controlled study

View ORCID ProfileO.V. Stanevich, View ORCID ProfileD.S. Fomina, View ORCID ProfileI.G. Bakulin, View ORCID ProfileSh. I. Galeev, View ORCID ProfileE.A. Bakin, View ORCID ProfileV.A. Belash, View ORCID ProfileA.N. Kulikov, View ORCID ProfileA.A. Lebedeva, View ORCID ProfileD.A. Lioznov, View ORCID ProfileYu S. Polushin, View ORCID ProfileI.V. Shlyk, View ORCID ProfileE.A. Vorobyev, S.V. Vorobyeva, T.V. Surovceva, View ORCID ProfileN.V. Bakulina, M.A. Lysenko, View ORCID ProfileI.S. Moiseev
doi: https://doi.org/10.1101/2021.04.20.21255662
O.V. Stanevich
1Pavlov University, Saint-Petersburg, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for O.V. Stanevich
  • For correspondence: oksana.stanevich@gmail.com
D.S. Fomina
2State City Hospital №52, Moscow, Russian Federation
5First Sechenov Moscow state medical University of the Ministry of Healthcare of the Russian Federation, Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for D.S. Fomina
I.G. Bakulin
3North-Western State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for I.G. Bakulin
Sh. I. Galeev
4State City Hospital №20, Saint-Petersburg, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sh. I. Galeev
E.A. Bakin
1Pavlov University, Saint-Petersburg, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for E.A. Bakin
V.A. Belash
1Pavlov University, Saint-Petersburg, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for V.A. Belash
A.N. Kulikov
1Pavlov University, Saint-Petersburg, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for A.N. Kulikov
A.A. Lebedeva
1Pavlov University, Saint-Petersburg, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for A.A. Lebedeva
D.A. Lioznov
1Pavlov University, Saint-Petersburg, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for D.A. Lioznov
Yu S. Polushin
1Pavlov University, Saint-Petersburg, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yu S. Polushin
I.V. Shlyk
1Pavlov University, Saint-Petersburg, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for I.V. Shlyk
E.A. Vorobyev
1Pavlov University, Saint-Petersburg, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for E.A. Vorobyev
S.V. Vorobyeva
1Pavlov University, Saint-Petersburg, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T.V. Surovceva
4State City Hospital №20, Saint-Petersburg, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N.V. Bakulina
3North-Western State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for N.V. Bakulina
M.A. Lysenko
2State City Hospital №52, Moscow, Russian Federation
6Pirogov Russian National Research Medical University (RNRMU) of the Ministry of Healthcare of the Russian Federation, Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
I.S. Moiseev
1Pavlov University, Saint-Petersburg, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for I.S. Moiseev
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Several anti-cytokine therapies were tested in the randomized trials in hospitalized patients with severe acute respiratory syndrome coronavirus 2 infection (COVID-19). Both janus kinase (JAK) inhibitor, baricitinib, and dexamethasone demonstrated the reduction of mortality. In this matched control study we compared dexamethasone to another JAK inhibitor, ruxolitinib.

Methods The study included 146 hospitalized patients with COVID-19 and oxygen support requirement. The control group was selected 1:1 from 1355 dexamethasone-treated patients and was matched by 29 clinical and laboratory parameters predicting survival.

Results Ruxolitinib treatment in the general cohort of patients was associated with equivalent to dexamethasone mortality rate: 9,6% (95% CI 4,6-14,6%) vs 13,0% (95% CI 7,5-18,5%, superiority p=0.35, non-inferiority p=0.0137), respectively. Time to discharge without oxygen support requirement was also not different between these groups: 13 vs 11 days (p=0.13). Subgroup analysis without adjustment for multiple comparisons demonstrated reduced mortality in ruxolitnib-treated patients with febrile fever (OR 0.33, 95%CI 0.11-1.00). Except higher incidence of grade 1 thrombocytopenia (37% vs 23%, p=0.042), ruxolitinib therapy was associated with better safety profile due to reduced rate of severe cardiovascular adverse events (6.8% vs 15%, p=0.025).

Conclusions Ruxolitinib may be an alternative anti-cytokine therapy with comparable efficacy in patients with potential risks of steroid administration. Patients with febrile fever at admission may benefit from ruxolitinib administration.

Funding Ruxolitinib was obtained from Novartis through Managed Access Program (MAP).

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT04337359

Funding Statement

Ruxolitinib was obtained from Novartis through Managed Access Program (MAP).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The details of the IRB/oversight body that provided approval or exemption for the research described are given below: IRB decision: The study protocol was approved by the biomedical ethics committee of I.P. Pavlov First Saint Petersburg State Medical University. IRB members: Edwin E. Zvartau, First Saint Petersburg State Pavlov Medical University, Valdman Institute of Pharmacology, head of IRB Vasiliy I. Trofimov, First Saint Petersburg State Pavlov Medical University, deputy head of IRB Marina V. Cherevkova, First Saint Petersburg State Pavlov Medical University, executive secretary Boris V. Afanasiev, First Saint Petersburg State Pavlov Medical University, committee member Svetlana V. Alimovna, First Saint Petersburg State Pavlov Medical University, committee member Tatiana N. Ketova, First Saint Petersburg State Pavlov Medical University, committee member Natalia V. Egorova, First Saint Petersburg State Pavlov Medical University, committee member Ashot M. Esayan, First Saint Petersburg State Pavlov Medical University, committee member Sergey M. Lazarev, First Saint Petersburg State Pavlov Medical University, committee member Alexey Y. Malikov, First Saint Petersburg State Pavlov Medical University, committee member Tatyana G. Medvedeva, First Saint Petersburg State Pavlov Medical University, committee member Yana I. Startseva, First Saint Petersburg State Pavlov Medical University, committee member Andrey Y. Cibin, First Saint Petersburg State Pavlov Medical University, committee member Yulia V. Emanuel, First Saint Petersburg State Pavlov Medical University, committee member

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

No applicable

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted April 20, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Ruxolitinib versus Dexamethasone in Hospitalized Adults with Covid-19: multicenter matched-controlled study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Ruxolitinib versus Dexamethasone in Hospitalized Adults with Covid-19: multicenter matched-controlled study
O.V. Stanevich, D.S. Fomina, I.G. Bakulin, Sh. I. Galeev, E.A. Bakin, V.A. Belash, A.N. Kulikov, A.A. Lebedeva, D.A. Lioznov, Yu S. Polushin, I.V. Shlyk, E.A. Vorobyev, S.V. Vorobyeva, T.V. Surovceva, N.V. Bakulina, M.A. Lysenko, I.S. Moiseev
medRxiv 2021.04.20.21255662; doi: https://doi.org/10.1101/2021.04.20.21255662
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Ruxolitinib versus Dexamethasone in Hospitalized Adults with Covid-19: multicenter matched-controlled study
O.V. Stanevich, D.S. Fomina, I.G. Bakulin, Sh. I. Galeev, E.A. Bakin, V.A. Belash, A.N. Kulikov, A.A. Lebedeva, D.A. Lioznov, Yu S. Polushin, I.V. Shlyk, E.A. Vorobyev, S.V. Vorobyeva, T.V. Surovceva, N.V. Bakulina, M.A. Lysenko, I.S. Moiseev
medRxiv 2021.04.20.21255662; doi: https://doi.org/10.1101/2021.04.20.21255662

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1101)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (502)
  • Epidemiology (9785)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2319)
  • Geriatric Medicine (223)
  • Health Economics (463)
  • Health Informatics (1563)
  • Health Policy (737)
  • Health Systems and Quality Improvement (606)
  • Hematology (238)
  • HIV/AIDS (507)
  • Infectious Diseases (except HIV/AIDS) (11657)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (240)
  • Medical Ethics (67)
  • Nephrology (258)
  • Neurology (2149)
  • Nursing (134)
  • Nutrition (338)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (518)
  • Oncology (1183)
  • Ophthalmology (366)
  • Orthopedics (129)
  • Otolaryngology (220)
  • Pain Medicine (148)
  • Palliative Medicine (50)
  • Pathology (313)
  • Pediatrics (698)
  • Pharmacology and Therapeutics (302)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2188)
  • Public and Global Health (4674)
  • Radiology and Imaging (781)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (624)
  • Rheumatology (274)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (210)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)